<Cites Alfonso, C. et al. 2006>

1. Allende, M. L., Zhou, D., Kalkofen, D. N., Benhamed, S., Tuymetova, G., & Borowski, C. et al. (2008). S1P1 receptor expression regulates emergence of NKT cells in peripheral tissues. FASEB Journal, 22(1), 307-315.

2. Brinkmann, V. (2007). Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacology and Therapeutics, 115(1), 84-105.

3. Hla, T., Venkataraman, K., & Michaud, J. (2008). The vascular S1P gradient-cellular sources and biological significance. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 1781(9), 477-482.

4. Huwiler, A., & Zangemeister-Wittke, U. (2007). Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Critical Reviews in Oncology/Hematology, 63(2), 150-159.

5. Neilson, J. R., Zheng, G. X. Y., Burge, C. B., & Sharp, P. A. (2007). Dynamic regulation of miRNA expression in ordered stages of cellular development. Genes and Development, 21(5), 578-589.

6. Sensken, S. -., Stäubert, C., Keul, P., Levkau, B., Schöneberg, T., & Gräler, M. H. (2008). Selective activation of G alpha i mediated signalling of S1P3 by FTY720-phosphate. Cellular Signalling, 20(6), 1125-1133.

<Cites Bologa, C., et al. 2006>

7. Alyea, R. A., Laurence, S. E., Kim, S. H., Katzenellenbogen, B. S., Katzenellenbogen, J. A., & Watson, C. S. (2008). The roles of membrane estrogen receptor subtypes in modulating dopamine transporters in PC-12 cells. Journal of Neurochemistry, 106(4), 1525-1533.

8. Biggins, J. B., & Koh, J. T. (2007). Chemical biology of steroid and nuclear hormone receptors. Current Opinion in Chemical Biology, 11(1), 99-110.

9. Boonyaratanakornkit, V., & Edwards, D. P. (2007). Receptor mechanisms mediating non-genomic actions of sex steroids. Seminars in Reproductive Medicine, 25(3), 139-153.

10. Chagin, A. S., & Sävendahl, L. (2007). Brief report: GPR30 estrogen receptor expression in the growth plate declines as puberty progresses. Journal of Clinical Endocrinology and Metabolism, 92(12), 4873-4877.

11. Cornil, C. A., Ball, G. F., & Balthazart, J. (2006). Functional significance of the rapid regulation of brain estrogen action: Where do the estrogens come from? Brain Research, 1126(1), 2-26.

12. Craig Jordan, V., Lewis-Wambi, J., Kim, H., Cunliffe, H., Ariazi, E., & Sharma, C. G. N. et al. (2007). Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients. Breast, 16(2 SUPPL.), 105-113.

13. Dodge, J. A., & Richardson, T. I. (2007). Chapter 10 novel selective estrogen receptor modulators (SERMs).

14. Feldman, R. D., & Gros, R. (2007). Choreographing the rapid vascular effects of estrogen: Sorting out the partners and the steps. Hypertension, 49(6), 1222-1224.

15. G. Shuker, D. E. (2007). Chemical genetics. Physical Chemistry Chemical Physics, 9(26), 165-173.

16. Gombos, K., Szele, E., Kiss, I., Varjas, T., Puskás, L., & Kozma, L. et al. (2007). Characterization of microarray gene expression profiles of early stage thyroid tumours. Cancer Genomics and Proteomics, 4(6), 403-410.

17. Goodnow Jr., R. A. (2006). Hit and lead identification: Integrated technology-based approaches. Drug Discovery Today: Technologies, 3(4), 367-375.

18. Huryn, D. M., & Cosford, N. D. P. (2007). Chapter 26 the molecular libraries screening center network (MLSCN): Identifying chemical probes of biological systems.

19. Insel, T. R. (2006). Translational research in the decade of discovery. Hormones and Behavior, 50(4), 504-505.

20. Javitt, N. B. (2008). Oxysterols: Novel biologic roles for the 21st century. Steroids, 73(2), 149-157.

21. Kamanga-Sollo, E., White, M. E., Chung, K. Y., Johnson, B. J., & Dayton, W. R. (2008). Potential role of G-protein-coupled receptor 30 (GPR30) in estradiol-17β-stimulated IGF-I mRNA expression in bovine satellite cell cultures. Domestic Animal Endocrinology, 35(3), 254-262.

22. Kelly, M. J., & Rønnekleiv, O. K. (2008). Membrane-initiated estrogen signaling in hypothalamic neurons. Molecular and Cellular Endocrinology, 290(1-2), 14-23.

23. Kirchmair, J., Distinto, S., Schuster, D., Spitzer, G., Langer, T., & Wolber, G. (2008). Enhancing drug discovery through in silico screening: Strategies to increase true positives retrieval rates. Current Medicinal Chemistry, 15(20), 2040-2053.

24. Knox, A. J. S., Yang, Y., Lloyd, D. G., & Meegan, M. J. (2008). Virtual screening of the estrogen receptor. Expert Opinion on Drug Discovery, 3(8), 853-866.

25. Kozikowski, A. P., Roth, B., & Tropsha, A. (2006). Why academic drug discovery makes sense [2]. Science, 313(5791), 1235-1236.

26. Kuhn, J., Dina, O. A., Goswami, C., Suckow, V., Levine, J. D., & Hucho, T. (2008). GPR30 estrogen receptor agonists induce mechanical hyperalgesia in the rat. European Journal of Neuroscience, 27(7), 1700-1709.

27. Lazo, J. S. (2006). Roadmap or roadkill: A pharmacologist’s analysis of the NIH molecular libraries initiative. Molecular Interventions, 6(5), 240-243.

28. Li, M., Ni, N., Chou, H. -., Lu, C. -., Tai, P. C., & Wang, B. (2008). Structure-based discovery and experimental verification of novel AI-2 quorum sensing inhibitors against vibrio harveyi. ChemMedChem, 3(8), 1242-1249.

29. Li, M., Huang, Y. -., Tai, P. C., & Wang, B. (2008). Discovery of the first SecA inhibitors using structure-based virtual screening. Biochemical and Biophysical Research Communications, 368(4), 839-845.

30. Madak-Erdogan, Z., Kieser, K. J., Sung, H. K., Komm, B., Katzenellenbogen, J. A., & Katzenellenbogen, B. S. (2008). Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Molecular Endocrinology, 22(9), 2116-2127.

31. Mintz, P. J., Habib, N. A., Jones, J. L., Giamas, G., Lewis, J. S., Bowen, R. L., et al. (2008). The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer. Cancer, 113(6), 1489-1495.

32. Muegge, I. (2008). Synergies of virtual screening approaches. Mini-Reviews in Medicinal Chemistry, 8(9), 927-933.

33. Muegge, I., & Oloff, S. (2006). Advances in virtual screening. Drug Discovery Today: Technologies, 3(4), 405-411.

34. Murphy, E., & Steenbergen, C. (2007). Gender-based differences in mechanisms of protection in myocardial ischemia-reperfusion injury. Cardiovascular Research, 75(3), 478-486.

35. Narita, S. -., Goldblum, R. M., Watson, C. S., Brooks, E. G., Estes, D. M., & Curran, E. M. et al. (2007). Environmental estrogens induce mast cell degranulation and enhance IgE-mediated release of allergic mediators. Environmental Health Perspectives, 115(1), 48-52.

36. Otto, C., Rohde-Schulz, B., Schwarz, G., Fuchs, I., Klewer, M., Brittain, D., et al. (2008). G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology, 149(10), 4846-4856.

37. Pang, Y., Dong, J., & Thomas, P. (2008). Estrogen signaling characteristics of atlantic croaker G protein-coupled receptor 30 (GPR30) and evidence it is involved in maintenance of oocyte meiotic arrest. Endocrinology, 149(7), 3410-3426.

38. Parker, C. N., & Bajorath, J. (2006). Towards unified compound screening strategies: A critical evaluation of error sources in experimental and virtual high-throughput screening. QSAR and Combinatorial Science, 25(12), 1153-1161.

39. Reddy, A. S., Pati, S. P., Kumar, P. P., Pradeep, H. N., & Sastry, G. N. (2007). Virtual screening in drug discovery - A computational perspective. Current Protein and Peptide Science, 8(4), 329-351.

40. Regitz-Zagrosek, V., Wintermantel, T. M., & Schubert, C. (2007). Estrogens and SERMs in coronary heart disease. Current Opinion in Pharmacology, 7(2), 130-139.

41. Romanò, N., Lee, K., Ábrahám, I. M., Jasoni, C. L., & Herbison, A. E. (2008). Nonclassical estrogen modulation of presynaptic GABA terminals modulates calcium dynamics in gonadotropin-releasing hormone neurons. Endocrinology, 149(11), 5335-5344.

42. Scott, P. -., Tremblay, A., Brochu, M., & St-Louis, J. (2007). Vasorelaxant action of 17β-estradiol in rat uterine arteries: Role of nitric oxide synthases and estrogen receptors. American Journal of Physiology - Heart and Circulatory Physiology, 293(6), H3713-H3719.

43. Spencer, J. L., Waters, E. M., Romeo, R. D., Wood, G. E., Milner, T. A., & McEwen, B. S. (2008). Uncovering the mechanisms of estrogen effects on hippocampal function. Frontiers in Neuroendocrinology, 29(2), 219-237.

44. Spencer, J. L., Waters, E. M., Milner, T. A., & McEwen, B. S. (2008). Estrous cycle regulates activation of hippocampal akt, LIM kinase, and neurotrophin receptors in C57BL/6 mice. Neuroscience, 155(4), 1106-1119.

45. Tikhonova, I. G., Chi, S. S., Neumann, S., Thomas, C. J., Raaka, B. M., & Costanzi, S. et al. (2007). Bidirectional, iterative approach to the structural delineation of the functional “chemoprint” in GPR40 for agonist recognition. Journal of Medicinal Chemistry, 50(13), 2981-2989.

46. Vasudevan, N., & Pfaff, D. W. (2007). Membrane-initiated actions of estrogens in neuroendocrinology: Emerging principles. Endocrine Reviews, 28(1), 1-19.

47. Vasudevan, N., & Pfaff, D. W. (2008). Non-genomic actions of estrogens and their interaction with genomic actions in the brain. Frontiers in Neuroendocrinology, 29(2), 238-257.

48. Wang, C., Dehghani, B., Magrisso, I. J., Rick, E. A., Bonhomme, E., Cody, D. B., et al. (2008). GPR30 contributes to estrogen-induced thymic atrophy. Molecular Endocrinology, 22(3), 636-648.

49. Weatherman, R. V. (2006). Untangling the estrogen receptor web. Nature Chemical Biology, 2(4), 175-176.

50. Wehling, M., & Lösel, R. (2006). Non-genomic steroid hormone effects: Membrane or intracellular receptors? Journal of Steroid Biochemistry and Molecular Biology, 102(1-5 SPEC. ISS.), 180-183.

51. Yang, J. Z., O’Flatharta, C., Harvey, B. J., & Thomas, W. (2008). Membrane ERα-dependent activation of PKCα in endometrial cancer cells by estradiol. Steroids, 73(11), 1110-1122.

<Cites Chun. J., et al. 2006>

52. Baumruker, T., Billich, A., & Brinkmann, V. (2007). FTY720, an immunomodulatory sphingolipid mimetic: Translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opinion on Investigational Drugs, 16(3), 283-289.

53. Brinkmann, V. (2007). Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacology and Therapeutics, 115(1), 84-105.

54. Dyatlovitskaya, E. V. (2007). The role of lysosphingolipids in the regulation of biological processes. Biochemistry (Moscow), 72(5), 479-484.

55. Dyatlovitskaya, E. V. (2008). Sphingolipid receptors. Biochemistry (Moscow), 73(2), 119-122.

56. Federico, L., Pamuklar, Z., Smyth, S. S., & Morris, A. J. (2008). Therapeutic potential of autotaxin/lysophospholipase D inhibitors. Current Drug Targets, 9(8), 698-708.

57. Hanessian, S., Charron, G., Billich, A., & Guerini, D. (2007). Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors. Bioorganic and Medicinal Chemistry Letters, 17(2), 491-494.

58. He, D., Natarajan, V., Stern, R., Gorshkova, I. A., Solway, J., Spannhake, E. W., et al. (2008). Lysophosphatidic acid-induced transactivation of epidermal growth factor receptor regulates cyclo-oxygenase-2 expression and prostaglandin E2 release via C/EBPβ in human bronchial epithelial cells. Biochemical Journal, 412(1), 153-162.

59. Meyer zu Heringdorf, D., & Jakobs, K. H. (2007). Lysophospholipid receptors: Signalling, pharmacology and regulation by lysophospholipid metabolism. Biochimica et Biophysica Acta - Biomembranes, 1768(4), 923-940.

60. Mitra, P., Payne, S. G., Milstien, S., & Spiegel, S. (2007). A rapid and sensitive method to measure secretion of sphingosine-1-phosphate

61. Myat, L. O., Thangada, S., Wu, M. -., Liu, C. H., Macdonald, T. L., & Lynch, K. R. et al. (2007). Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. Journal of Biological Chemistry, 282(12), 9082-9089.

62. Ogretmen, B. (2006). Sphingolipids in cancer: Regulation of pathogenesis and therapy. FEBS Letters, 580(23), 5467-5476.

63. Peters, S. L., & Alewijnse, A. E. (2007). Sphingosine-1-phosphate signaling in the cardiovascular system. Current Opinion in Pharmacology, 7(2), 186-192.

64. Rhim, J. -., Jang, I. -., Song, K. -., Ha, M. -., Cho, S. -., Yeo, E. -., et al. (2008). Lysophosphatidic acid and adenylyl cyclase inhibitor increase proliferation of senescent human diploid fibroblasts by inhibiting adenosine monophosphate-activated protein kinase. Rejuvenation Research, 11(4), 781-792.

65. Ryan, J. J., & Spiegel, S. (2008). The role of sphingosine-1-phosphate and its receptors in asthma. Drug News and Perspectives, 21(2), 89-96.

66. Seuwen, K., Ludwig, M. -., & Wolf, R. M. (2006). Receptors for protons or lipid messengers or both? Journal of Receptors and Signal Transduction, 26(5-6), 599-610.

67. Stahl, D., & Sibrowski, W. (2006). Editorial: Hot topic: Autoimmunity. Current Pharmaceutical Design, 12(2), 129-130.

68. Yatomi, Y. (2008). Plasma sphingosine 1-phosphate metabolism and analysis. Biochimica Et Biophysica Acta - General Subjects, 1780(3), 606-611.

69. Ye, X. (2008). Lysophospholipid signaling in the function and pathology of the reproductive system. Human Reproduction Update, 14(5), 519-536.

70. Zhang, Z., & Schluesener, H. J. (2007). FTY720: A most promising immunosuppressant modulating immune cell functions. Mini-Reviews in Medicinal Chemistry, 7(8), 845-850.

71. Zhao, Y., He, D., Zhao, J., Wang, L., Leff, A. R., & Spannhake, E. W. et al. (2007). Lysophosphatidic acid induces interleukin-13 (IL-13) receptor α2 expression and inhibits IL-13 signaling in primary human bronchial epithelial cells. Journal of Biological Chemistry, 282(14), 10172-10179.

72. Zhao, Z., Xiao, Y., Elson, P., Tan, H., Plummer, S. J., & Berk, M. et al. (2007). Plasma lysophosphatidylcholine levels: Potential biomarkers for colorectal cancer. Journal of Clinical Oncology, 25(19), 2696-2701.

<Cites Edwards, B., et al. 2006>

73. Muller, C. D., Peluso, J., Tabaka-Moreira, H., Taquet, N., Dumont, S., & Reimund, J. -. (2007). Can flow cytometry play a part in cell based high-content screening? Cytometry Part A, 71(11), 901-904.

74. Smith, R. W., Robinson, J. P., Zucker, R. M., Geddes, C., Kachelmeier, A., McConnell, G., et al. (2008). Perspectives on cellular analysis: Linking quantitation to structure and function by instrumental methods and analysis. Microscopy and Microanalysis, 14(SUPPL. 2), 752-753.

75. Grimberg, B. T., Erickson, J. J., Sramkoski, R. M., Jacobberger, J. W., & Zimmerman, P. A. (2008). Monitoring plasmodium falciparum growth and development by UV flow cytometry using an optimized hoechst-thiazole orange staining strategy. Cytometry Part A, 73(6), 546-554.

<Cites Fara, D.C., et al. 2006>

76. Oprea, T. I., Tropsha, A., Faulon, J. -., & Rintoul, M. D. (2007). Systems chemical biology. Nature Chemical Biology, 3(8), 447-450.

77. Piras, P., & Roussel, C. (2008). A screening study of ChirBase molecular database to explore the expanded chiral pool derived from the application of chiral chromatography. Journal of Pharmaceutical and Biomedical Analysis, 46(5), 839-847.

78. Waszkowycz, B. (2008). Towards improving compound selection in structure-based virtual screening. Drug Discovery Today, 13(5-6), 219-226.

<Cites Hensler, M., et al. 2006>

79. Dolle, R. E., Le Bourdonnec, B., Goodman, A. J., Morales, G. A., Salvino, J. M., & Zhang, W. (2007). Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2006. Journal of Combinatorial Chemistry, 9(6), 855-902.

80. Metwally, N. H. (2008). A novel synthesis of 1,4-bis(thiopyrano[2,3-d] thiazolyl) benzene derivatives. Heterocycles, 75(2), 319-329.

81. Mitchell, M. O. (2007). Antibacterial agents against methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Anti-Infective Agents in Medicinal Chemistry, 6(4), 243-247.

82. Zhang, Z., Wang, P., Ding, N., Song, G., & Li, Y. (2007). Total synthesis of cleistetroside-2, partially acetylated dodecanyl tetrarhamnoside derivative isolated from cleistopholis patens and cleistopholis glauca. Carbohydrate Research, 342(9), 1159-1168.

83. Berlinck, R. G. S., Burtoloso, A. C. B., & Kossuga, M. H. (2008). The chemistry and biology of organic guanidine derivatives. Natural Product Reports, 25(5), 919-954.

<Cites Inglese, J. et al 2006>

84. Koehn, F. E. (2008). High impact technologies for natural products screening

85. Johnston, P. A., Soares, K. M., Shinde, S. N., Foster, C. A., Shun, T. Y., Takyi, H. K., et al. (2008). Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay and Drug Development Technologies, 6(4), 505-518.

86. Eckenhoff, R. G., Zheng, W., & Kelz, M. B. (2008). From anesthetic mechanisms research to drug discovery. Clinical Pharmacology and Therapeutics, 84(1), 144-148.

87. Niles, A. L., Moravec, R. A., & Riss, T. L. (2008). Update on in vitro cytotoxicity assays for drug development. Expert Opinion on Drug Discovery, 3(6), 655-669.

88. Judson, R., Elloumi, F., Woodrow, R. W., Li, Z., & Shah, I. (2008). A comparison of machine learning algorithms for chemical toxicity classification using a simulated multi-scale data model. BMC Bioinformatics, 9

89. Koehn, F. E. (2008). New strategies and methods in the discovery of natural product anti-infective agents: The mannopeptimycins. Journal of Medicinal Chemistry, 51(9), 2613-2617.

90. Kavlock, R. J., Ankley, G., Blancato, J., Breen, M., Conolly, R., Dix, D., et al. (2008). Reviews: Computational toxicology - A state of the science mini review. Toxicological Sciences, 103(1), 14-27.

91. Zhu, H., Rusyn, I., Richard, A., & Tropsha, A. (2008). Use of cell viability assay date improves the prediction accuracy of conventional quantitative structure-activity relationships models of animal carcinogenicity. Environmental Health Perspectives, 116(4), 506-513.

92. Loukas, A., & Bethony, J. M. (2008). New drugs for an ancient parasite. Nature Medicine, 14(4), 365-367.

93. Hämäläinen, M. D., Zhukov, A., Ivarsson, M., Fex, T., Gottfries, J., Karlsson, R., et al. (2008). Label-free primary screening and affinity ranking of fragment libraries using parallel analysis of protein panels. Journal of Biomolecular Screening, 13(3), 202-209.

94. Zhijin Wu, Dongmei Liu, & Yunxia Sui. (2008). Quantitative assessment of hit detection and confirmation in single and duplicate high-throughput screenings. Journal of Biomolecular Screening, 13(2), 159-167.

95. Collins, F. S., Gray, G. M., & Bucher, J. R. (2008). Transforming environmental health protection. Science, 319(5865), 906-907.

96. Schröter, T., Minond, D., Weiser, A., Dao, C., Habel, J., Spicer, T., et al. (2008). Comparison of miniaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled luciferase high-throughput screening assays to discover inhibitors of rho-kinase II (ROCK-II). Journal of Biomolecular Screening, 13(1), 17-28.

97. Hozjan, V., Guo, K., Wu, X., & Oppermann, U. (2008). Ligand supplementation as a method to increase soluble heterologous protein production. Expert Review of Proteomics, 5(1), 137-143.

98. Rodrigues, D. J., Lyons, R., Laflin, P., Pointon, W., & Kammonen, J. (2007). A three-stage experimental strategy to evaluate and validate an interplate IC50 format. Assay and Drug Development Technologies, 5(6), 805-813.

99. Huryn, D. M., & Cosford, N. D. P. (2007). Chapter 26 the molecular libraries screening center network (MLSCN): Identifying chemical probes of biological systems

100. Kozarich, J. W. (2007). New LSD therapies unfolding. Chemistry and Biology, 14(9), 976-977.

101. Dams, G., Van Acker, K., Gustin, E., Vereycken, I., Bunkens, L., Holemans, P., et al. (2007). A time-resolved fluorescence assay to identify small-molecule inhibitors of HIV-1 fusion. Journal of Biomolecular Screening, 12(6), 865-874.

102. Wetzel, S., Schuffenhauer, A., Roggo, S., Ertl, P., & Waldmann, H. (2007). Cheminformatic analysis of natural products and their chemical space. Chimia, 61(6), 355-360.

103. Agrafiotis, D. K., Bandyopadhyay, D., Wegner, J. K., & Van Vlijmen, H. (2007). Recent advances in chemoinformatics. Journal of Chemical Information and Modeling, 47(4), 1279-1293.

104. Lazo, J. S., Brady, L. S., & Dingledine, R. (2007). Building a pharmacological lexicon: Small molecule discovery in academia. Molecular Pharmacology, 72(1), 1-7.

105. Johnston, P. A., Foster, C. A., Tong, Y. S., Skoko, J. J., Shinde, S., Wipf, P., et al. (2007). Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors. Assay and Drug Development Technologies, 5(3), 319-332.

106. Dove, A. (2007). High-throughput screening goes to school. Nature Methods, 4(6), 523-532.

107. Jones, J., Rodgers, J., Heil, M., May, J., White, L., Maddry, J. A., et al. (2007). High throughput drug screening for human immunodeficiency virus type 1 reactivating compounds. Assay and Drug Development Technologies, 5(2), 181-189.

108. Fenton, R. A., & Knepper, M. A. (2007). Urea and renal function in the 21st century: Insights from knockout mice. Journal of the American Society of Nephrology, 18(3), 679-688.

109. Sidransky, E., LaMarca, M. E., & Ginns, E. I. (2007). Therapy for gaucher disease: Don’t stop thinking about tomorrow. Molecular Genetics and Metabolism, 90(2), 122-125.

110. Schuffenhauer, A., Ertl, P., Roggo, S., Wetzel, S., Koch, M. A., & Waldmann, H. (2007). The scaffold tree - visualization of the scaffold universe by hierarchical scaffold classification. Journal of Chemical Information and Modeling, 47(1), 47-58.

111. Li, A., Mustafi, D., Fu, Q., Tereshko, V., Chen, D. L., Tice, J. D., et al. (2006). Nanoliter microfluidic hybrid method for simultaneous screening and optimization validated with crystallization of membrane proteins. Proceedings of the National Academy of Sciences of the United States of America, 103(51), 19243-19248.

112. Shoichet, B. K. (2006). Interpreting steep dose-response curves in early inhibitor discovery. Journal of Medicinal Chemistry, 49(25), 7274-7277.

113. Collins, I., & Workman, P. (2006). New approaches to molecular cancer therapeutics. Nature Chemical Biology, 2(12), 689-700.

114. Lazo, J. S. (2006). Roadmap or roadkill: A pharmacologist’s analysis of the NIH molecular libraries initiative. Molecular Interventions, 6(5), 240-243.

<Cites Lazo, J. et al 2006>

115. Xie, X. -., & Chen, J. -. (2008). Data mining a small molecule drug screening representative subset from NIH PubChem. Journal of Chemical Information and Modeling, 48(3), 465-475.

116. Rishton, G. M. (2008). Molecular diversity in the context of leadlikeness: Compound properties that enable effective biochemical screening. Current Opinion in Chemical Biology, 12(3), 340-351.

<Cites Mayer, T. et al 2006>

117. Houck, K. A., & Kavlock, R. J. (2008). Understanding mechanisms of toxicity: Insights from drug discovery research. Toxicology and Applied Pharmacology, 227(2), 163-178.

118. Svahn, M. G., Rabe, K. S., Barger, G., El-Andaloussi, S., Simonson, O. E., Didier, B., et al. (2008). High-throughput identification of combinatorial ligands for DNA delivery in cell culture. Paper presented at the , 1062 73-88.

<Cites Nefzi, A., et al. 2006>

119. Bodnar, R. J. (2007). Endogenous opiates and behavior: 2006. Peptides, 28(12), 2435-2513.

120. Dolle, R. E., Le Bourdonnec, B., Goodman, A. J., Morales, G. A., Salvino, J. M., & Zhang, W. (2007). Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2006. Journal of Combinatorial Chemistry, 9(6), 855-902.

121. Edwards, P. (2007). Manipulating molecular architecture in parallel. Drug Discovery Today, 12(3-4), 183-184.

122. Hahn, F., & Schepers, U. (2007). Solid phase chemistry for the directed synthesis of biologically active polyamine analogs, derivatives, and conjugates.

<Cites Oprea, T., et al. 2006>

123. Schuffenhauer, A., & Brown, N. (2006). Chemical diversity and biological activity. Drug Discovery Today: Technologies, 3(4), 387-395.

124. Cheng, A. C. (2008). Chapter 2 predicting selectivity and druggability in drug discovery

<Cites Parker, C., et al. 2006>

125. Guido, R. V. C., Oliva, G., & Andricopulo, A. D. (2008). Virtual screening and its integration with modern drug design technologies. Current Medicinal Chemistry, 15(1), 37-46.

126. Shah, J. Z., & Bt Salim, N. (2007). A soft hierarchical algorithm for the clustering of multiple bioactive chemical compounds. 4414 LNBI 140-153.

127. Southan, C., Várkonyi, P., & Muresan, S. (2007). Complementarity between public and commercial databases: New opportunities in medicinal chemistry informatics. Current Topics in Medicinal Chemistry, 7(15), 1502-1508.

128. Sirois, S., & Cloutier, L. M. (2008). Needed: System dynamics for the drug discovery process. Drug Discovery Today, 13(15-16), 708-715.

129. Cloutier, L. M., & Sirois, S. (2008). Bayesian versus frequentist statistical modeling: A debate for hit selection from HTS campaigns. Drug Discovery Today, 13(11-12), 536-542.

<Cites Sanna, M., et al. 2006>

130. Baumruker, T., Billich, A., & Brinkmann, V. (2007). FTY720, an immunomodulatory sphingolipid mimetic: Translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opinion on Investigational Drugs, 16(3), 283-289.

131. Brinkmann, V. (2007). Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacology and Therapeutics, 115(1), 84-105.

132. Cahalan, M. D., & Parker, I. (2008). Choreography of cell motility and interaction dynamics imaged by two-photon microscopy in lymphoid organs

133. Cooke, N., & Zécri, F. (2007). Chapter 16 sphingosine 1-phosphate type 1 receptor modulators: Recent advances and therapeutic potential.

134. Dev, K. K., Mullershausen, F., Mattes, H., Kuhn, R. R., Bilbe, G., & Hoyer, D. et al. (2008). Brain sphingosine-1-phosphate receptors: Implication for FTY720 in the treatment of multiple sclerosis. Pharmacology and Therapeutics, 117(1), 77-93.

135. Foss Jr., F. W., Snyder, A. H., Davis, M. D., Rouse, M., Okusa, M. D., & Lynch, K. R. et al. (2007). Synthesis and biological evaluation of γ-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorganic and Medicinal Chemistry, 15(2), 663-677.

136. Gonzalez-Cabrera, P. J., Hla, T., & Rosen, H. (2007). Mapping pathways downstream of sphingosine 1-phosphate subtype 1 by differential chemical perturbation and proteomics. Journal of Biological Chemistry, 282(10), 7254-7264.

137. Hänel, P., Andréani, P., & Gräler, M. H. (2007). Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB Journal, 21(4), 1202-1209.

138. Hla, T., Venkataraman, K., & Michaud, J. (2008). The vascular S1P gradient-cellular sources and biological significance. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 1781(9), 477-482.

139. Horga, A., & Montalban, X. (2008). FTY720 (fingolimod) for relapsing multiple sclerosis. Expert Review of Neurotherapeutics, 8(5), 699-714.

140. Huryn, D. M., & Cosford, N. D. P. (2007). Chapter 26 the molecular libraries screening center network (MLSCN): Identifying chemical probes of biological systems.

141. Jo, S. -., Bajwa, A., Awad, A. S., Lynch, K. R., & Okusa, M. D. (2008). Sphingosine-1-phosphate receptors: Biology and therapeutic potential in kidney disease. Kidney International, 73(11), 1220-1230.

142. Kihara, A., & Igarashi, Y. (2008). Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 1781(9), 496-502.

143. Lazo, J. S. (2006). Roadmap or roadkill: A pharmacologist’s analysis of the NIH molecular libraries initiative. Molecular Interventions, 6(5), 240-243.

144. Lazo, J. S., Brady, L. S., & Dingledine, R. (2007). Building a pharmacological lexicon: Small molecule discovery in academia. Molecular Pharmacology, 72(1), 1-7.

145. Marsolais, D., Hahm, B., Edelmann, K. H., Walsh, K. B., Guerrero, M., Hatta, Y., et al. (2008). Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza. Molecular Pharmacology, 74(3), 896-903.

146. Meyer zu Heringdorf, D., & Jakobs, K. H. (2007). Lysophospholipid receptors: Signalling, pharmacology and regulation by lysophospholipid metabolism. Biochimica et Biophysica Acta - Biomembranes, 1768(4), 923-940.

147. Murph, M., & Mills, G. B. (2007). Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Reviews in Molecular Medicine, 9(28), 1-18.

148. Nakamura, T., Yonesu, K., Mizuno, Y., Suzuki, C., Sakata, Y., & Takuwa, Y. et al. (2007). Synthesis and SAR studies of a novel class of S1P1 receptor antagonists. Bioorganic and Medicinal Chemistry, 15(10), 3548-3564.

149. Nombela-Arrieta, C., Mempel, T. R., Soriano, S. F., Mazo, I., Wymann, M. P., & Hirsch, E. et al. (2007). A central role for DOCK2 during interstitial lymphocyte motility and sphingosine-1-phosphate-mediated egress. Journal of Experimental Medicine, 204(3), 497-510.

150. Omori, K., Shikata, Y., Sarai, K., Watanabe, N., Wada, J., & Goda, N. et al. (2007). Edaravone mimics sphingosine-1-phosphate-induced endothelial barrier enhancement in human microvascular endothelial cells. American Journal of Physiology - Cell Physiology, 293(5), C1523-C1531.

151. Osinde, M., Mullershausen, F., & Dev, K. K. (2007). Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology, 52(5), 1210-1218.

152. Oskeritzian, C. A., Milstien, S., & Spiegel, S. (2007). Sphingosine-1-phosphate in allergic responses, asthma and anaphylaxis. Pharmacology and Therapeutics, 115(3), 390-399.

153. Petrie, H. T., & Zúñiga-Pflücker, J. C. (2007). Zoned out: Functional mapping of stromal signaling microenvironments in the thymus.

154. Pham, T. H. M., Okada, T., Matloubian, M., Lo, C. G., & Cyster, J. G. (2008). S1P1 receptor signaling overrides retention mediated by gαi-coupled receptors to promote T cell egress. Immunity, 28(1), 122-133.

155. Rao, R. P., & Acharya, J. K. (2008). Sphingolipids and membrane biology as determined from genetic models. Prostaglandins and Other Lipid Mediators, 85(1-2), 1-16.

156. Rapizzi, E., Donati, C., Cencetti, F., Nincheri, P., & Bruni, P. (2008). Sphingosine 1-phosphate differentially regulates proliferation of C2C12 reserve cells and myoblasts. Molecular and Cellular Biochemistry, 314(1-2), 193-199.

157. Rivera, J., Proia, R. L., & Olivera, A. (2008). The alliance of sphingosine-1-phosphate and its receptors in immunity. Nature Reviews Immunology, 8(10), 753-763.

158. Ryan, J. J., & Spiegel, S. (2008). The role of sphingosine-1-phosphate and its receptors in asthma. Drug News and Perspectives, 21(2), 89-96.

159. Schultz, C. (2006). Lipid-induced phenotypes. Nature Chemical Biology, 2(8), 396-398.

160. Schwab, S. R., & Cyster, J. G. (2007). Finding a way out: Lymphocyte egress from lymphoid organs. Nature Immunology, 8(12), 1295-1301.

161. Sensken, S. -., Stäubert, C., Keul, P., Levkau, B., Schöneberg, T., & Gräler, M. H. (2008). Selective activation of G alpha i mediated signalling of S1P3 by FTY720-phosphate. Cellular Signaling, 20(6), 1125-1133.

162. Skoura, A., Sanchez, T., Claffey, K., Mandala, S. M., Proia, R. L., & Hla, T. (2007). Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. Journal of Clinical Investigation, 117(9), 2506-2516.

163. Spiegel, S., & Milstien, S. (2007). Functions of the multifaceted family of sphingosine kinases and some close relatives. Journal of Biological Chemistry, 282(4), 2125-2129.

164. Takabe, K., Paugh, S. W., Milstien, S., & Spiegel, S. (2008). Inside-out signaling of sphingosine-1-phosphate: Therapeutic targets. Pharmacological Reviews, 60(2), 181-195.

165. Worbs, T., Bernhardt, G., & Förster, R. (2008). Factors governing the intranodal migration behavior of T lymphocytes. Immunological Reviews, 221(1), 44-63.

166. Wymann, M. P., & Schneiter, R. (2008). Lipid signaling in disease. Nature Reviews Molecular Cell Biology, 9(2), 162-176.

<Cites Tessema, M., et al. 2006>

167. Stein, V., Sielaff, I., Johnsson, K., & Hollfelder, F. (2007). A covalent chemical genotype-phenotype linkage for in vitro protein evolution. ChemBioChem, 8(18), 2191-2194.

168. Corrie, S. R., Lawrie, G. A., Battersby, B. J., Ford, K., Rühmann, A., Koehler, K., et al. (2008). Quantitative data analysis methods for bead-based DNA hybridization assays using generic flow cytometry platforms. Cytometry Part A, 73(5), 467-476.